Gilead price target raised to $100 from $89 at Lazard Capital

theflyonthewall.com

Lazard Capital raised its price target for Gilead citing increased confidence in the company's Hepatitis C virus franchise and reiterates a Buy rating on the stock.

View Comments (0)